Steady Growth in Crohn's Disease Treatment Market: $11.13B in 2023 to $11.76B in 2024 at 5.6% CAGR

The crohn's disease (cd) treatment market size has grown strongly in recent years. It will grow from $11.13 billion in 2023 to $11.76 billion in 2024 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to rising prevalence of crohn's disease, growing awareness of the disease, government initiatives, changing lifestyle.

The crohn's disease (cd) treatment market size is expected to see steady growth in the next few years. It will grow to $14.22 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to growing demand for combination therapies, increasing adoption of biologics, investments in research and development on crohn's disease (cd) treatments. Major trends in the forecast period include development biologic drugs, innovative products, advanced diagnostic tools, biosimilars adoption.

Market Overview -
Crohn's disease (CD) is an inflammatory bowel disease (IBD) that causes inflammation and swelling of the tissues in the digestive tract. Crohn's disease (CD) treatment involves various approaches, therapies, medications and interventions to manage and control the symptoms and complications of a chronic inflammatory condition.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12902&type=smp

Increasing Prevalence Of Inflammatory Bowel Diseases Fuels Growth In The Crohn'S Disease Treatment Market
The increasing prevalence of inflammatory bowel diseases is expected to propel the growth of the Crohn's disease (CD) treatment market going forward. Inflammatory bowel disease (IBD) is a group of chronic inflammatory disorders primarily affecting the gastrointestinal (GI) tract. Crohn's disease (CD) treatment offers relief from symptoms, reduces inflammation, promotes remission and enhances the overall quality of life for individuals suffering from chronic inflammatory bowel disease. For instance, in May 2021, according to BioMed Central Ltd., a UK-based scientific open-access publisher, it is expected that between 2020 and 2035, there will be 69 thousand Inflammatory bowel disease cases in Iran, 220 thousand cases in the Middle East, 2.2 million cases in India and 4.5 million cases in East Asia. Therefore, the increasing prevalence of inflammatory bowel diseases drives the Crohn's disease (CD) treatment market.

Competitive Landscape -
Major players in the crohn's disease (cd) treatment market are Pfizer Inc., Johnson and Johnson Ltd., Merck and Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Perrigo Company PLC, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC.

Market Leaders Innovate With Ibdsense Technology In The Crohn'S Disease Treatment Market
Major companies operating in the Crohn's disease (CD) treatment market are introducing new technologies, such as IBDSENSE, to sustain their position in the market. For instance, in March 2023, The IRR Chemistry Hub, a Scotland-based interdisciplinary hub, developed IBDSENSE. This technology aims to improve inflammatory bowel disease diagnosis and monitoring using non-invasive methods, including Crohn's disease. The project uses fluorescence-based technology to measure the enzyme activity of Granzyme B (GzmB) in patient biosamples. This technology aims to improve the patient experience and treatment choices.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/crohn's-disease-cd-treatment-global-market-report

Key Segments -
The crohn's disease (cd) treatment market covered in this report is segmented -
1) By Drug Type: Antibiotics; Amino Salicylates; Corticosteroids; Immunomodulators; Other Drug Types
2) By Route of Administration: Oral; Injectable
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Drug Stores

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.